This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2021
  • /
  • 6
  • /
  • FDA end of phase II meeting leaves InRhythm on tra...

FDA end of phase II meeting leaves InRhythm on track for phase III trials and filing in atrial fibrillation.- InCarda Therapeutics

Read time: 1 mins
Published:25th Jun 2021
InCarda Therapeutics announced that it has successfully completed an End-of-Phase II (EOP2) meeting with the FDA for InRhythm (flecainide for inhalation) for the treatment of atrial fibrillation.

The official EOP2 meeting minutes highlight agreement between FDA and InCarda that a single Phase III trial of 400 patients will be acceptable to support the filing of a New Drug Application (NDA) for InRhythm for the acute conversion of recent-onset paroxysmal atrial fibrillation (PAF) to sinus rhythm (SR). The company remains on track to initiate the pivotal Phase III trial of InRhythm (RESTORE1) in recent-onset PAF patients during the third quarter of 2021, with data readout expected in the second half of 2022.

The therapy is being developed initially for use in a medically supervised setting such as a hospital or emergency room and subsequently as a portable treatment that can be self-administered by patients in a non-medically supervised setting (such as the home). The Phase II program demonstrated that InRhythm can safety and rapidly convert recent onset PAF to SR, with a median time to conversion of approximately eight minutes after completing the administration of the treatment.

Condition: Atrial Fibrillation
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.